American Thyroid Association (ATA) National Thyroid Cancer Workshop II Frontiers in Thyroid Cancer: ATA Guidelines in Clinical Practice

DRAFT PROGRAM (11/16/2008)

Friday, January 23, 2009

7:00 am – 7: 50 am	Continental Breakfast
7:50 am – 8:00 am	Welcome and ATA Guideline Comments David S. Cooper
8:00 am – 8:30 am	Thyroid Nodules: Diagnostic and Therapeutic Dilemmas Hossein Gharib (QざA at 9:30 am)
8:30 am – 9:00 am	Preoperative and Initial Surgical Management of DTC: Extent of Thyroid and Lymph Node Surgery Gerard M. Doherty (Q&A at 9:30 am)
9:00 am – 9:30 am	Postoperative I-131 Remnant Ablation and Therapy: Risk and Benefits, I-131 Dosimetry vs. Empiric Therapy <i>Bryan R. Haugen (QざA at 9:30 am)</i>
9:30 am– 10:00 am	Questions and Answers Moderator: Susan J. Mandel <i>Hossein Gharib, Gerard M. Doherty, Bryan R. Haugen</i>
10:00 am – 10:25 am	BREAK (in the Exhibit Hall)
10:25 am – 11:00 am	New Paradigms and Problems in the Follow-Up of DTC: US, Tg and Imaging <i>Martin Schlumberger</i> <i>Include audience Q</i> ざA
11:00 am – 12:00 pm	Panel Discussion: Initial Management of Low and High Risk Tumors Session Chair: David S. Cooper Gerard M. Doherty, Stephanie L. Lee and Furio Pacini Include audience Q&A
12:00 pm – 12:30 pm	BREAK (Pick up lunch in the exhibit hall)
12:30 pm – 1:20 pm	Meet the Professor Luncheons Based on Case Studies (Ticket required to attend workshops)
	<i>Susan J. Mandel</i> : Neck US for Thyroid Nodules, DTC, and Lymph Node Metastases
	<i>Gary L. Francis:</i> Pediatric Differentiated and Medullary Thyroid Cancer

12:30 pm – 1:20 pm	Meet the Professor Luncheons Based on Case Studies (cont.) (Ticket required to attend workshops)
	R. Michael Tuttle: Management of DTC Distant Metastases
	<i>David S. Cooper</i> . TSH Suppression in DTC: Who and How Much?
	<i>Stephanie L. Lee</i> : Management of Low Risk DTC Patients
1:20 pm – 1:30 pm	BREAK (transition back to the general session)
1:30 pm – 2:30 pm	Debate: Which Thyroid Nodules Should Undergo FNA? Moderator: Richard T. Kloos Susan J. Mandel and Bryan R. Haugen Include audience Q&A
2:30 pm – 3:30 pm	Debate: Prophylactic Central Neck Dissection in PTC Moderator: Ernest L. Mazzaferri Gerard M. Doherty and David L. Steward Include audience Q&A
3:30 pm – 4:00 pm	BREAK (in the Exhibit Hall)
4:00 pm – 5:00 pm	Debate: Radioiodine Ablation for Low Risk PTC Moderator: Matthew D. Ringel Ernest L. Mazzaferri and R. Michael Tuttle Include audience Q&A
5:00 pm – 5:30 pm	DTC Molecular-Based Therapy and Clinical Trials Steven I. Sherman Include audience QさA
5:30 pm– 6:30 pm	Panel Discussion: Case Management Distant Metastases Moderator: Steven I. Sherman Jeffrey F. Moley, Martin Schlumberger and Matthew D. Ringel Include audience QヴA
6:30 pm – 7:00 pm	Questions and Answers Covering the Full Day Moderator: Bryan R. Haugen David C. Cooper, Stephanie L. Lee, and David L. Steward
7:00 pm	Adjourn

Saturday, January 24, 2009

7:00 am – 7:50 am	Continental Breakfast
7:50 am – 8:00 am	Welcome and ATA Guideline Comments Richard T. Kloos
8:00 am – 8:30 am	Anaplastic Thyroid Cancer Steven I. Sherman Include audience Q&A
8:30 am – 9:30 am	Panel Discussion: Observation vs. Resection of Persistent DTC Lymph Node Metastases Session Chair: David L. Steward Jeffrey F. Moley, Martin Schlumberger, Douglas B. Evans and Hossein Gharib Include audience Q&A
9:30 am – 10:00 am	Special Problems: Managing DTC During Pregnancy and in Elderly Patients Steven I. Sherman Include audience Q&A
10:00 am – 10:30 am	BREAK (in the Exhibit Hall)
10:30 am – 11:30 am	Panel Discussion: High Serum Tg Levels and Negative Whole Body Scans Session Chair: Bryan Haugen David L. Steward, Hossein Gharib and Furio Pacini Include audience QざA
11:30 am – 12:00 pm	When to Stop Treating with Radioiodine R. Michael Tuttle Include audience QdeA
12:00 pm – 12:30 pm	BREAK (Pick up lunch in the exhibit hall)
12:30 pm – 1:20 pm	Meet the Professor Luncheons Based on Case Studies (Ticket required to attend workshops)
	<i>Matthew D. Ringel:</i> FNA needle washout for Thyroglobulin and Calcitonin
	<i>Gary L. Francis:</i> Pediatric Differentiated and Medullary Thyroid Cancer
	R. Michael Tuttle: Management of DTC Distant Metastases
	<i>David S. Cooper.</i> TSH Suppression in DTC: Who and How Much?

	Stephanie L. Lee: Management of Low Risk DTC Patients
1:20 pm – 1:30 pm	BREAK (transition back to the general session)
1:30 pm – 2:00 pm	Management of Thyroglobulin-antibody Positive DTC Patients Ernest L. Mazzaferri Include audience Q&A
2:00 pm – 2:30 pm	Prophylactic Surgery for Medullary Thyroid Cancer: Timing and Outcome Douglas B. Evans (Q&A at 3:30 pm)
2:30 pm – 3:00 pm	Therapeutic Surgery for MTC: Preoperative Evaluation of Clinically Apparent Disease and the Extent of Surgery Jeffrey F. Moley (Q&A at 3:30 pm)
3:00 pm – 3:30 pm	When to use External Beam Radiation or Chemoembolization in DTC or MTC Robert T. Gagel (Q&A at 3:30 pm)
3:30 pm – 4:00 pm	Questions and Answers Moderator: Douglas B. Evans <i>Jeffrey F. Moley, Robert T. Gagel</i>
4:00 pm – 4:30 pm	BREAK (in the Exhibit Hall)
4:30 pm – 5:00 pm	MTC Molecular-Based Therapy and Clinical Trials Samuel A. Wells, Jr Include audience Q&A
5:00 pm – 5:30 pm	MEN 2 Associated Pheochromocytoma and Hyperparathyroidism Douglas B. Evans Include audience Q&A
5:30 pm – 6:30 pm	Panel Discussion: Case Management of MTC Session Chair: Furio Pacini Samuel A. Wells, Jr., Robert T. Gagel, and Richard T. Kloos Include audience Q&A
6:30 pm – 7:00 pm	Questions and Answers Covering the Full Day Moderator: Robert T. Gagel Samuel A. Wells, Jr., Furio Pacini, and Richard T. Kloos
7:00 pm	Adjourn